Immunomic Therapeutics, Inc. is sponsoring a travel fund for patients enrolled in the ATTAC-II trial
A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma (NCT02465268)
This clinical trial is a vaccine therapy for the treatment of newly diagnosed Glioblastoma Multiforme patients. The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor called glioblastoma (GBM) when given with stronger doses of routine chemotherapy.
Duane Mitchell, MD, PhD, University of Florida
- University of Florida, Gainesville, FL
- Orlando Health, Orlando, FL
- Duke University Medical Center, Durham, North Carolina
Sponsors and Collaborators
- University of Florida
- National Cancer Institute (NCI)
Travel Fund Details
Travel for enrolled patients living more than 100 miles away from the trial sites will be sponsored for the duration of treatment.
Included Travel Arrangements
- Roundtrip coach flights for the patient and up to 1 caregiver
- Hotel accommodations for each visit (1-2 nights, depending on treatment)
- Car rental for each visit